Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey - (:unkn) unknown (CIG MEDIA GROUP, LP, 2019)
Keywords: elotuzumab; immunomodulatory drugs; Multiple myeloma